AKRO Quote, Financials, Valuation and Earnings

Biogen has a net margin of -- compared to Akero Therapeutics's net margin of 10.87%. Akero Therapeutics's return on equity of -- beat Biogen's return on equity of 10.33%.

Akero Therapeutics has a consensus price target of $77.64, signalling upside risk potential of 72.99%. On the other hand Biogen has an analysts' consensus of $201.18 which suggests that it could grow by 40.16%. Given that Akero Therapeutics has higher upside potential than Biogen, analysts believe Akero Therapeutics is more attractive than Biogen.

Akero Therapeutics has a beta of -0.193, which suggesting that the stock is 119.294% less volatile than S&P 500. In comparison Biogen has a beta of 0.012, suggesting its less volatile than the S&P 500 by 98.773%.

Akero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akero Therapeutics pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Akero Therapeutics quarterly revenues are --, which are smaller than Biogen quarterly revenues of $2.5B. Akero Therapeutics's net income of -$70M is lower than Biogen's net income of $266.7M. Notably, Akero Therapeutics's price-to-earnings ratio is -- while Biogen's PE ratio is 12.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics is -- versus 2.17x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Cytokinetics has a net margin of -- compared to Akero Therapeutics's net margin of -886.28%. Akero Therapeutics's return on equity of -- beat Cytokinetics's return on equity of --.

Akero Therapeutics has a consensus price target of $77.64, signalling upside risk potential of 72.99%. On the other hand Cytokinetics has an analysts' consensus of $79.10 which suggests that it could grow by 76.13%. Given that Cytokinetics has higher upside potential than Akero Therapeutics, analysts believe Cytokinetics is more attractive than Akero Therapeutics.

Akero Therapeutics has a beta of -0.193, which suggesting that the stock is 119.294% less volatile than S&P 500. In comparison Cytokinetics has a beta of 0.949, suggesting its less volatile than the S&P 500 by 5.057%.

Akero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akero Therapeutics pays -- of its earnings as a dividend. Cytokinetics pays out -- of its earnings as a dividend.

Akero Therapeutics quarterly revenues are --, which are smaller than Cytokinetics quarterly revenues of $16.9M. Akero Therapeutics's net income of -$70M is higher than Cytokinetics's net income of -$150M. Notably, Akero Therapeutics's price-to-earnings ratio is -- while Cytokinetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics is -- versus 271.64x for Cytokinetics. Usually stocks with elevated PS ratios are considered overvalued.

89bio has a net margin of -- compared to Akero Therapeutics's net margin of --. Akero Therapeutics's return on equity of -- beat 89bio's return on equity of --.

Akero Therapeutics has a consensus price target of $77.64, signalling upside risk potential of 72.99%. On the other hand 89bio has an analysts' consensus of $27.55 which suggests that it could grow by 216.61%. Given that 89bio has higher upside potential than Akero Therapeutics, analysts believe 89bio is more attractive than Akero Therapeutics.

Akero Therapeutics has a beta of -0.193, which suggesting that the stock is 119.294% less volatile than S&P 500. In comparison 89bio has a beta of 1.346, suggesting its more volatile than the S&P 500 by 34.566%.

Akero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 89bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akero Therapeutics pays -- of its earnings as a dividend. 89bio pays out -- of its earnings as a dividend.

Akero Therapeutics quarterly revenues are --, which are smaller than 89bio quarterly revenues of --. Akero Therapeutics's net income of -$70M is higher than 89bio's net income of -$118.4M. Notably, Akero Therapeutics's price-to-earnings ratio is -- while 89bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics is -- versus -- for 89bio. Usually stocks with elevated PS ratios are considered overvalued.

Sage Therapeutics has a net margin of -- compared to Akero Therapeutics's net margin of -747.33%. Akero Therapeutics's return on equity of -- beat Sage Therapeutics's return on equity of -63.59%.

Akero Therapeutics has a consensus price target of $77.64, signalling upside risk potential of 72.99%. On the other hand Sage Therapeutics has an analysts' consensus of $8.05 which suggests that it could grow by 4.22%. Given that Akero Therapeutics has higher upside potential than Sage Therapeutics, analysts believe Akero Therapeutics is more attractive than Sage Therapeutics.

Akero Therapeutics has a beta of -0.193, which suggesting that the stock is 119.294% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.817, suggesting its less volatile than the S&P 500 by 18.337%.

Akero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akero Therapeutics pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

Akero Therapeutics quarterly revenues are --, which are smaller than Sage Therapeutics quarterly revenues of $12.8M. Akero Therapeutics's net income of -$70M is higher than Sage Therapeutics's net income of -$95.8M. Notably, Akero Therapeutics's price-to-earnings ratio is -- while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics is -- versus 11.37x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.